Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

Lexicon Pharmaceuticals (NASDAQ: LXRX) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) on the same day, where management will discuss the quarterly results and provide a business update. Interested participants can access the webcast through the Events page on Lexicon's investor website, while those wishing to ask questions during the call can register to receive dial-in information. An archived version of the webcast will be made available on the company's website for later viewing.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference 2025. The company's management will deliver a presentation on Wednesday, April 9, at 8:00 a.m. ET.

Investors and interested parties can access both the live event and a replay of the presentation through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Lexicon Pharmaceuticals (LXRX) has entered into an exclusive worldwide license agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin drug candidate targeting obesity and metabolic disorders. The deal includes potential payments of up to $1 billion, with $75 million in upfront and near-term milestone payments.

LX9851 is a selective oral small molecule inhibitor of ACSL5, targeting fat accumulation and energy balance regulation. Preclinical data from Obesity Week 2024 demonstrated that LX9851, when combined with semaglutide, significantly reduced weight, food intake, and fat mass compared to semaglutide alone. The drug also showed positive effects on liver steatosis and mitigated weight regain after semaglutide discontinuation.

Under the agreement, Novo Nordisk will handle IND filing, development, manufacturing, and commercialization, while Lexicon completes IND-enabling activities. Lexicon will receive tiered royalties on net sales in addition to milestone payments.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the Leerink Partners Global Healthcare Conference 2025 in Miami. The company's management will engage in a fireside chat scheduled for Wednesday, March 12, at 10:00 a.m. ET. Both the live presentation and a subsequent replay will be made available to interested parties through the Events section of Lexicon's investor relations website at investors.lexpharma.com.

Lexicon Pharmaceuticals (LXRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its R&D pipeline. The company's Q4 2024 revenues increased to $26.6 million from $0.7 million in Q4 2023, including a $25.0 million upfront payment from the Viatris INPEFA licensing agreement.

Key developments include positive topline results from the PROGRESS Phase 2b study of pilavapadin (LX9211) for diabetic peripheral neuropathic pain, with the 10 mg dose advancing to Phase 3 development in 2025. The company is also progressing with LX9851 for obesity and continuing enrollment in the SONATA HCM Phase 3 trial for sotagliflozin.

Financial highlights show Q4 2024 net loss of $33.8 million ($0.09 per share), compared to $49.8 million ($0.20 per share) in Q4 2023. R&D expenses increased to $26.7 million, while SG&A expenses slightly decreased to $32.3 million. The company ended 2024 with $238.0 million in cash and short-term investments.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) on the same day to discuss the financial performance and provide a business update.

Investors can access the conference call through the Events page on Lexicon's investor website. Those interested in asking questions during the call can register to receive dial-in information and a unique PIN. An archived version of the webcast will be available for later viewing on the company's website.

Lexicon Pharmaceuticals (LXRX) has announced topline results from its Phase 2b PROGRESS study evaluating pilavapadin (LX9211), an oral non-opioid treatment for diabetic peripheral neuropathic pain (DPNP). The study achieved its objectives with the 10 mg dose, showing meaningful pain reduction versus placebo and improved tolerability.

The 10 mg dose demonstrated a reduction of 1.74 in mean average daily pain score (ADPS) compared to 1.31 in placebo. While the study's primary endpoint did not reach statistical significance (p=0.11), the 10 mg dose showed early and sustained clinically meaningful separation from placebo. Adverse events, primarily dizziness and nausea, were mild to moderate and significantly improved compared to the previous RELIEF-DPN-1 study.

Based on these results, Lexicon plans to advance the 10 mg dose into Phase 3 development, positioning pilavapadin to potentially become the first oral non-opioid treatment approved for neuropathic pain in 20 years.

Lexicon Pharmaceuticals (LXRX) has scheduled a conference call and webcast for March 3, 2025, at 8:00 a.m. ET to present topline results from their Phase 2b PROGRESS study. The study evaluates pilavapadin (LX9211), an oral, non-opioid investigational drug that inhibits adaptor-associated kinase 1 (AAK1), for treating moderate to severe diabetic peripheral neuropathic pain (DPNP) in adults.

The PROGRESS trial is designed as a dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension. Interested participants can access the live conference call and webcast through the company's investor relations website, with an archived version to be made available afterward.

Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that The Lancet Diabetes & Endocrinology published a study highlighting the unique efficacy of sotagliflozin in reducing major adverse cardiovascular events (MACE). The study, a secondary analysis of the SCORED randomized trial, demonstrated that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, significantly reduced the risk of heart attack (MI) and stroke in patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and high cardiovascular (CV) risk.

Patients on sotagliflozin had a lower rate of MACE outcomes (4.8 events per 100 person-years [p-y]) compared to placebo (6.3 events per 100 p-y) with a hazard ratio (HR) of 0.77, 95% confidence interval (CI) of 0.65-0.91, and P=0.002. The drug also reduced the rate of MI (1.8 events per 100 p-y vs. 2.7 events per 100 p-y, HR: 0.68, 95% CI: 0.52-0.89, P=0.004) and stroke (1.2 events per 100 p-y vs. 1.8 events per 100 p-y, HR: 0.66, 95% CI: 0.48-0.91, P=0.012).

Dr. Deepak L. Bhatt, Director at Mount Sinai Fuster Heart Hospital, emphasized that sotagliflozin is the only SGLT inhibitor to show significant reductions in both heart attack and stroke.